Bimagrumab Side Effects: What Studies Report

What bimagrumab is, and where the safety data come from

Bimagrumab (BYM338) is a fully human monoclonal antibody that blocks activin type II receptors, and review articles have described it as an investigational agent studied for inclusion body myositis, sarcopenia and medication-associated lean body mass loss rather than an approved therapy (PMID 41248895). Because it is an antibody given intravenously in clinical studies, essentially all published human safety information comes from company- and investigator-run randomised trials and their extensions, not from routine clinical practice.

That matters for how the adverse-event picture should be read. The events described below are those that trial investigators recorded and reported in study populations with defined characteristics — older adults with sarcopenia, adults with sporadic inclusion body myositis, and adults with obesity or type 2 diabetes — over follow-up periods measured in months to a few years. Readers who want the underlying mechanism, trial design and endpoint background in more depth can work through the PeptideU bimagrumab course; this page stays on what studies reported about tolerability and harms.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or investigational compound.

Adverse Events in Obesity and Type 2 Diabetes Trials: What Studies Report

The most frequently discussed human dataset comes from a phase 2 randomised clinical trial in adults with type 2 diabetes and obesity, in which researchers administered bimagrumab 10 mg/kg (capped at 1,200 mg) intravenously every 4 weeks for 48 weeks and reported a large reduction in total body fat mass alongside an increase in lean mass compared with placebo (PMID 33439265). In the same report, the study team characterised the antibody as generally tolerated, with mild muscle spasms, acne and diarrhoea among the adverse events noted in the treated group (PMID 33439265).

A later randomised phase 2 trial examined bimagrumab and semaglutide alone or in combination in adults with obesity, and the investigators reported that the combination shifted body composition toward greater fat loss with preservation of lean mass relative to semaglutide alone (PMID 41772149). In that trial report, muscle spasms and gastrointestinal events such as diarrhoea were again among the adverse events described, consistent with what earlier bimagrumab studies had recorded (PMID 41772149).

Narrative reviews of obesity pharmacotherapy have placed bimagrumab within a pipeline of agents being evaluated specifically for their effects on body composition rather than weight alone, and have noted that tolerability and long-term safety remain open questions for this class (PMID 38302593). A separate review of pharmacological approaches to fat loss with lean mass preservation in overweight and type 2 diabetes reached a similar framing, describing promising body-composition findings alongside unresolved safety and durability questions (PMID 41178728).

Adverse Events in Sporadic Inclusion Body Myositis Trials: What Studies Report

The largest and longest human exposure to bimagrumab reported in the literature is in sporadic inclusion body myositis (sIBM). A pooled long-term safety and tolerability analysis in sIBM reported that the most frequently recorded adverse events in treated participants included diarrhoea, muscle spasms and falls (PMID 32690797). Falls are notable in this context because the underlying disease itself causes progressive weakness, so investigators had to interpret such events against a background of disease progression rather than attributing them automatically to treatment.

The long-term extension of the RESILIENT trial followed participants beyond the core double-blind period, and researchers reported that the extension did not surface new safety concerns beyond the event types already described in the core study, while efficacy on the primary functional endpoint had not been demonstrated (PMID 33597289). That combination — an acceptable tolerability profile without a positive functional result — is the reason the sIBM programme is frequently cited in reviews as a safety dataset rather than an efficacy success (PMID 41248895).

Adverse Events in Sarcopenia Trials: What Studies Report

In an early phase 2 proof-of-concept study in older adults with sarcopenia, researchers gave a single intravenous dose of bimagrumab 30 mg/kg and followed participants for 24 weeks, reporting increases in thigh muscle volume and lean body mass with a reduction in fat mass compared with placebo (PMID 28653345). The same report described muscle cramps or spasms, mild diarrhoea and acne among the adverse events recorded in treated participants (PMID 28653345).

A later randomised trial compared bimagrumab 700 mg intravenously every 4 weeks for 24 weeks against optimised standard of care in community-dwelling older adults with sarcopenia, and the study reported gains in lean mass and losses in fat mass without a corresponding advantage on the functional endpoints assessed (PMID 33074327). Muscle spasms and diarrhoea were again among the adverse events the investigators reported in the treated arm (PMID 33074327). A broader review of sarcopenia management summarised these trials as showing consistent body-composition effects with tolerability that did not, by itself, halt development, while emphasising that muscle mass gains did not reliably translate into measured physical performance (PMID 40580805).

Reported adverse events by study setting

Why muscle spasms and diarrhoea recur across reports

Two features of the reported event profile stand out. First, muscle spasms or cramps appeared across multiple independent programmes, including the diabetes and obesity trial (PMID 33439265) and the sarcopenia studies (PMID 28653345). Second, diarrhoea was reported in both muscle-disease and metabolic populations, including the pooled sIBM safety analysis (PMID 32690797). Review authors have discussed these as the characteristic tolerability signals associated with activin type II receptor blockade as a drug class (PMID 41248895).

Acne has been described less consistently but appeared in more than one report, including the proof-of-concept sarcopenia study (PMID 28653345) and the type 2 diabetes trial (PMID 33439265). Published pharmacokinetic and pharmacodynamic work has characterised bimagrumab exposure and its relationship to changes in lean and fat mass across clinical studies, which is the framework investigators used when interpreting whether events tracked with exposure (PMID 36527600).

What the published record does not report

Several questions are simply not answered by the papers available, and stating that absence plainly is more useful than extrapolating:

• Use outside supervised trials. The published human studies administered bimagrumab intravenously in monitored research settings (PMID 33439265); the literature summarised here does not describe safety outcomes for material obtained or used outside those settings.
• Very long-term exposure in metabolic populations. The longest safety follow-up reported is in the inclusion body myositis programme (PMID 33597289), not in obesity, where reported trials ran for months rather than years (PMID 33439265).
• Pregnancy, lactation and paediatric use. None of the verified reports summarised here addressed these populations.
• Head-to-head safety against other body-composition agents. Reviews have positioned bimagrumab within a developing pipeline rather than reporting comparative safety rankings (PMID 38302593, PMID 41178728).
• Whether body-composition change equals clinical benefit. The sarcopenia trial reported lean mass gains without a matching functional advantage (PMID 33074327), a limitation echoed in the sarcopenia treatment literature (PMID 40580805).

How to read tolerability language in these papers

Phrases such as "generally well tolerated" describe a study population over a fixed period under protocol monitoring; they are not a statement about individual risk. The sIBM extension illustrates the distinction: researchers reported no new safety concerns during extended follow-up while the programme did not demonstrate the functional benefit it was designed to show (PMID 33597289). Similarly, the pooled sIBM safety analysis counted falls as frequent events in a population whose disease causes falls, which is why event frequency alone cannot establish causation (PMID 32690797).

Bimagrumab is not an approved medicine, and questions about individual suitability, monitoring or interaction with other therapies fall to a licensed clinician. The material here reports what published investigators observed and wrote; it is not guidance, and no part of it should be read as a recommendation to use any compound.

References

• Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial (JAMA Network Open, 2021)
• Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (Nature Medicine, 2026)
• Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT (Neurology, 2021)
• Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis (Neurology, 2020)
• Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial (JAMA Network Open, 2020)
• Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study (Journal of the American Geriatrics Society, 2017)
• Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338) (Clinical Pharmacokinetics, 2023)
• Bimagrumab: Novel Medical Therapy for Inclusion Body Myositis, Sarcopenia, and Medication-Induced Lean Body Mass Loss (Cardiology in Review, 2025)
• Therapeutic advances in sarcopenia management: From traditional interventions to personalized medicine (Clinical Nutrition, 2025)
• What is the pipeline for future medications for obesity? (International Journal of Obesity, 2025)
• Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes (Diabetes, Obesity & Metabolism, 2026)